Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

Abstract Background Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated. The overarching goal of the Genetic Overlap between Meta...

Full description

Bibliographic Details
Main Authors: Vasiliki Mamakou, Sophie Hackinger, Eleni Zengini, Evgenia Tsompanaki, Eirini Marouli, Ioannis Serafetinidis, Bram Prins, Athina Karabela, Eirini Glezou, Lorraine Southam, Nigel W. Rayner, Karoline Kuchenbaecker, Klea Lamnissou, Vassilis Kontaxakis, George Dedoussis, Fragiskos Gonidakis, Anastasia Thanopoulou, Nikolaos Tentolouris, Eleftheria Zeggini
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Psychiatry
Subjects:
Type 2 diabetes
Schizophrenia
First generation antipsychotics
Second generation antipsychotics
Antidepressants
Mood stabilizers
Online Access:http://link.springer.com/article/10.1186/s12888-018-1826-4

Internet

http://link.springer.com/article/10.1186/s12888-018-1826-4

Similar Items